PRESS RELEASE Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025  Ladenburg, Germany, 26 March 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it will be presenting its latest ADC research results and  [ … ]

PRESS RELEASE Heidelberg Pharma announces financial figures and reports on successful business performance in 2024 Promising data from clinical trial with HDP-101 in multiple myeloma, including a complete remission in one female patient; study is making good progress Received first approvals for the clinical study with ATAC candidate HDP-102; st [ … ]

PRESS RELEASE Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty HealthCare Royalty and Heidelberg Pharma amend royalty financing agreement to provide for USD 20 million payment Heidelberg Pharma extends cash runway into 2027 Ladenburg, Germany, 13 March 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company  [ … ]

Ad hoc announcement - Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014 Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty HealthCare Royalty and Heidelberg Pharma amend royalty financing agreement to provide for USD 20 million payment Heidelberg Pharma extends cash runway into 2027 Ladenburg, Ger [ … ]

PRESS RELEASE Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma HDP-101 is well tolerated to date, with no signs of dose-limiting toxicities Complete remission observed in one patient from Cohort 5 Proprietary novel payload with a unique mode of action, representing new [ … ]